GRCE Stock Analysis: Buy, Sell, or Hold?
GRCE - Grace Therapeutics, Inc. Common Stock
$5.13
0.25 (5.12%)
▲
5d:
+7.55%
30d:
+32.56%
90d:
+48.27%
HOLD
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: Feb 12, 2026
0d
Get Alerted When GRCE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: GRCE is 10.6% above fair value ($4.64). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: GRCE is 10.6% above fair value ($4.64). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: GRCE is currently trading at $5.13, which is considered extended relative to its 30-day fair value range of $3.96 to $4.64.
Technical Outlook: Technically, GRCE is in a strong uptrend. The price is approaching resistance at $5.18. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: GRCE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.29 (+120.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GRCE is in a strong uptrend. The price is approaching resistance at $5.18. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: GRCE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.29 (+120.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$3.96 -
$4.64
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+10.6% above fair value)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.1%)
- BULLISH: Trading 120.0% below Wall St target ($11.29)
Fair Price Analysis
30-Day Fair Range
$3.96 -
$4.64
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$4.32
Resistance Level
$5.18
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.82
Wall Street Target
$11.29
(+120.0%)
Share & Embed Analysis
Last updated: April 05, 2026 9:20 PM ET
Data refreshes hourly during market hours. Next update: 10:20 PM
Data refreshes hourly during market hours. Next update: 10:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRCE showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 65 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 57 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 61 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 50 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 61 BUY |